Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.45 |
| ▸ | NEK3 | P51956 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.45 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633623 | 0.79 | TBK1 (0.51) | BRAFAURKAHPGDSSTK17ANEK3 | |
| SCHEMBL1633767 | 0.78 | HRH3 (0.53) | AURKASTK17ANEK3LIMK1NEK5 | |
| SCHEMBL13362845 | 0.78 | STK17A (0.55) | BRAFAURKASTK17ANEK3LIMK1 | |
| SCHEMBL1634724 | 0.77 | IKBKB (0.62) | BRAFAURKA | |
| SCHEMBL1633534 | 0.77 | AURKA (0.56) | BRAFAURKASTK17ANEK3LIMK1 | |
| SCHEMBL14146531 | 0.76 | STK17A (0.56) | BRAFAURKASTK17ANEK3LIMK1 | |
| SCHEMBL8738919 | 0.76 | ALDH1A1 (0.64) | — | |
| SCHEMBL12671670 | 0.75 | STK17A (0.55) | BRAFAURKASTK17ANEK3LIMK1 | |
| SCHEMBL3319061 | 0.75 | STK17A (0.55) | BRAFAURKASTK17ANEK3LIMK1 | |
| SCHEMBL21835437 | 0.75 | BRAF (0.56) | BRAFPIN1STK17ABTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 334/4885AURKA 576/4885PIN1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.